5628 results for "*oma"

in 32.32 milliseconds.

• Gut microbiota biomarkers associated with Multiple Myeloma: The REMNANT Study

  We aimed to investigate the association between gut microbiota composition and multiple myeloma–related clinical parameters, including treatment response, clinical outcomes, and treatment-related adverse effects

  Study EGAS50000002142

• scRNAseq data from HNSCC biopsies before and after BA treatment

  Tumor biopsies from 6 head and neck small cell carcinoma (HNSCC) berfore and 3-weeks after bintrafusp-alfa (BA) treatment were analyzed using single-cell RNA sequencing.

  Study EGAS50000002114

• CIML Lymphoma Single-Cell Atlas Project

  Data Accession Committee for evaluating requests for accessing the sequence-level data produced by CIML investigators in the frame of the Lymphoma Single-Cell Atlas Project.

  Dac EGAC50000001133

• Norwegian Sarcoma Consortium Data Access Committee for datasets submitted to FEGA Norway

  This is the Data Access Committee appointed by Oslo University Hospital for the Norwegian Sarcoma Consortium datasets submitted to FEGA Norway, under the Regional Ethical Approval 944504.

  Dac EGAC50000001153

• NoSarC -- Norwegian Sarcoma Consortium. Towards individualized therapy for orphan cancer.

  This study is initiated and conducted by the Norwegian Sarcoma Consortium - a collaboration between 5 Norwegian hospitals and universities, coordinated by Oslo University Hospital. The NoSarC project was initiated in 2014 and aimed to perform molecular characterization of samples from a national, population-based cohort of sarcoma patients, to identify tumors which are sensitive to therapies already developed and approved for more common cancers. The NoSarC cohort in this study consists of Tumor-Normal pairs from 287 subjects that has been Whole Exome Sequenced.

  Study EGAS50000002163

• Cell-Free DNA Genomic and Fragmentomic Features for Early Outcome Prediction in Diffuse Large B-Cell Lymphoma

  Purpose: Diffuse large B-cell lymphoma (DLBCL) patients need an accurate and early risk stratification strategy as prompt therapy escalation may improve outcome. Patients and methods: We evaluated cell free DNA (cfDNA) genomic and fragmentomic features in 190 patients with large B-cell lymphoma from more than 40 hospitals in the Benelux using Whole Genome Sequencing (WGS). We defined a new metric called ACT score (Aberrations, Contribution of short fragments, Terminal motif analyses) by combining four cfDNA signals and evaluated its performance to predict end-of-treatment (EOT) response and survival. Results: Individual cfDNA features and ACT score were altered per EOT response after one cycle of treatment (T1). The ACT score at T1 outperformed all individual cfDNA features in predicting EOT response (AUC = 0.74). Patients with a positive ACT score had an inferior outcome compared to ACT score negative patients [progression-free survival (PFS): HR 5.0 (95% CI 3.1-8.2), log-rank test, p < 0.0001) and overall survival (OS): HR 6.5 (95% CI 3.5-12.2), log-rank test, p < 0.0001]. The 2-year PFS in ACT score positive and negative patients were 29.8% and 78.1%, respectively. The prognostic value of the ACT score is independent of the International Prognostic Index and interim imaging. Conclusions: ACT score computed from a single plasma sample collected after one cycle of treatment can predict clinical outcome. This low-cost and easy-to-interpret test does not require tissue biopsies or a priori knowledge of mutations and has the potential to aid patient selection in interventional clinical trials and risk-adapted treatment strategies.

  Study EGAS50000000412

• SCANDARE HNSCC

  Prospective biobanking study in SCANDARE HNSCC (Head and Neck Squamous Cell Carcinoma) patients aiming at better understand the link between the molecular alterations of the tumor itself, its microenvironment and immune response.

  Study EGAS50000001158

• Orthotopic Patient-Derived Organoid Model Reveals Tumor Microenvironment-Dependent Phenotypes in Lung Squamous Cell Carcinoma-WTS

  RNAseq data

  Study EGAS50000002025

• Orthotopic Patient-Derived Organoid Model Reveals Tumor Microenvironment-Dependent Phenotypes in Lung Squamous Cell Carcinoma-WGS

  WGS

  Study EGAS50000002026

• Orthotopic Patient-Derived Organoid Model Reveals Tumor Microenvironment-Dependent Phenotypes in Lung Squamous Cell Carcinoma-WES

  WES data

  Study EGAS50000002027